Insider Selling: Cardlytics (NASDAQ:CDLX) CEO Sells $28,526.22 in Stock

Cardlytics, Inc. (NASDAQ:CDLXGet Free Report) CEO Amit Gupta sold 6,498 shares of Cardlytics stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $4.39, for a total value of $28,526.22. Following the sale, the chief executive officer owned 123,490 shares of the company’s stock, valued at approximately $542,121.10. This represents a 5.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Amit Gupta also recently made the following trade(s):

  • On Monday, July 6th, Amit Gupta sold 9,640 shares of Cardlytics stock. The shares were sold at an average price of $4.39, for a total transaction of $42,319.60.

Cardlytics Price Performance

NASDAQ:CDLX traded down $0.10 on Monday, reaching $4.37. The stock had a trading volume of 58,856 shares, compared to its average volume of 103,822. Cardlytics, Inc. has a 12-month low of $4.25 and a 12-month high of $32.80. The company has a market cap of $25.39 million, a price-to-earnings ratio of -0.25 and a beta of 0.61. The firm’s fifty day moving average is $6.37 and its two-hundred day moving average is $8.75.

Analysts Set New Price Targets

A number of analysts recently issued reports on CDLX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Cardlytics in a research report on Friday, April 10th. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a research note on Thursday, June 18th. Lake Street Capital set a $10.00 price objective on Cardlytics in a report on Friday, May 8th. Finally, Wall Street Zen lowered Cardlytics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Two analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $10.00.

View Our Latest Stock Report on Cardlytics

Institutional Investors Weigh In On Cardlytics

A number of institutional investors have recently bought and sold shares of CDLX. Quinn Opportunity Partners LLC raised its stake in Cardlytics by 900.0% during the third quarter. Quinn Opportunity Partners LLC now owns 1,100,000 shares of the company’s stock worth $2,673,000 after purchasing an additional 990,000 shares during the period. Voleon Capital Management LP purchased a new stake in shares of Cardlytics during the 3rd quarter valued at $127,000. Goldman Sachs Group Inc. increased its holdings in shares of Cardlytics by 15.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 109,001 shares of the company’s stock worth $125,000 after buying an additional 14,273 shares during the last quarter. Centiva Capital LP acquired a new stake in shares of Cardlytics during the 3rd quarter worth $104,000. Finally, Algert Global LLC purchased a new position in shares of Cardlytics in the 3rd quarter worth $100,000. 68.10% of the stock is currently owned by hedge funds and other institutional investors.

Cardlytics Company Profile

(Get Free Report)

Cardlytics, Inc operates a purchase intelligence and marketing platform that connects advertisers with consumers through bank and credit card transaction data. The company partners with financial institutions to analyze anonymized purchase information, enabling brands to deliver highly targeted offers and rewards directly to customers’ online and mobile banking channels. By leveraging real-time insights into consumer spending habits, Cardlytics helps marketers optimize campaign performance and measure return on ad spend more accurately than traditional digital advertising methods.

At the core of Cardlytics’ offering is its proprietary purchase intelligence engine, which aggregates and anonymizes transaction data from partner banks and credit unions.

See Also

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.